Cannabis Law Report

OCTOBER 9, 2021

Indeed, studies conducted by world renowned medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of conditions including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress. Please join us in cosponsoring this legislation, thank you.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59

Policy Safety Marijuana Data 59

SpeedWeed

MARCH 18, 2021

for the production of cannabis used in federally-regulated clinical trials. Early on in the study, criticism over the poor quality and low potency of the NIDA-supplied cannabis prompted Johns Hopkins University to withdraw from the multi-year clinical trials. He has covered the legal cannabis industry since 2010.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

The Cannigma

OCTOBER 19, 2021

A clinical trial published in 2015 found that the test subjects had “significantly higher blood THC” levels when they used cannabis along with alcohol, and combining the two led to increased performance impairment. A 2010 study found that consuming alcohol “slightly prolonged” the half-life of THC in the blood.

Research and Development 128

Research and Development Clinical Trials Edibles THC 128

Cannabis Law Report

JULY 28, 2021

Cepharanthine is on its way to establishing itself as a once per day, oral anti-cancer therapeutic with a well-established safety profile which will pave the way for an expedited clinical development pathway and future partnering opportunities with pharmaceutical companies. Epub 2010 Dec 17. ” Next Steps. 647) 202-1824.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. However, from 2010, a dramatic increase is observable in articles about medicinal cannabis in the publications under analysis.

Research and Development 52

Research and Development Medicine Access Media 52